NCT00096551View on ClinicalTrials.gov

A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 1, 2004

Primary Completion Date

December 11, 2009

Study Completion Date

July 25, 2011

Conditions
Prostatic Neoplasms
Interventions
DRUG

Recombinant Vaccinia-PSA(L155)/TRICOM (PROSTVAC-V/TRICOM)

DRUG

Recombinant Fowlpox-PSA(L155)/TRICOM (PROSTVAC-F/TRICOM)

DRUG

Recombinant Fowlpox-GM-CSF

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00096551 - A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy | Biotech Hunter | Biotech Hunter